带机械球囊的点阵式创新血流导向装置：未破裂颅内动脉瘤治疗的新突破与疗效评估

Lattice innovative flow diverter with mechanical balloons: a new breakthrough and efficacy evaluation in the treatment of unruptured intracranial aneurysms.

作者信息

Sun Xufeng, Peng Yueyang, Li Bin, Zhang Mengyuan, Wen Zhifeng

机构信息

Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.

Fuxin People's Hospital (Fuxin Women and Children's Medical Center), Fuxin, China.

出版信息

Front Med (Lausanne). 2025 Sep 10;12:1612754. doi: 10.3389/fmed.2025.1612754. eCollection 2025.

DOI:10.3389/fmed.2025.1612754

PMID:41001394

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12457356/

Abstract

PURPOSE

The Lattice Innovative Flow Diverter with Mechanical Balloons (Lattice FD-MB) provides superior positioning accuracy and wall apposition during deployment, potentially addressing the limitations of traditional mesh stents in treating complex lesions. However, clinical data on the efficacy and safety of the Lattice FD-MB for unruptured intracranial aneurysms (UIAs) remain limited. This study evaluates the effectiveness and safety of the Lattice FD-MB in UIA treatment.

METHODS

We retrospectively analyzed 29 UIA patients treated with the Lattice FD-MB at our institution between October 2023 and October 2024. After the operation, digital subtraction angiography (DSA) and computed tomography angiography (CTA) were performed to assess aneurysm occlusion. Clinical follow-up, including modified Rankin scale (mRS) scores and DSA, was conducted at 3, 6, and 12 months postoperatively.

RESULTS

The Lattice FD-MB was successfully deployed in all patients, achieving a 100% procedural success rate with no intraoperative device-related failures. Intraoperative complications occurred in two cases (6.9%). Postoperatively, 27 patients (93.1%) showed favorable clinical outcomes, defined as no new neurological deficits or hemorrhagic/ischemic events. At discharge, functional outcomes (mRS) were as follows: mRS 0 (no symptoms) in 23 patients (79.3%), mRS 1 (no significant disability) in 3 patients (10.3%), and mRS 2 (slight disability) in 3 patients (10.3%). On follow-up, the proportion of patients with mRS 0 increased over time, with 82.8% (24/29) at 3 months, 86.2% (25/29) at 6 months, and 89.7% (26/29) at 12 months, demonstrating sustained clinical stability and neurological improvement.

CONCLUSION

The Lattice FD-MB appears to be a feasible and safe treatment for UIAs, with promising patient outcomes. Further research is warranted to investigate prognostic factors influencing long-term results after Lattice FD-MB treatment.

摘要

目的

带有机械球囊的点阵式创新血流导向装置（Lattice FD-MB）在展开过程中提供了卓越的定位精度和血管壁贴合度，有可能解决传统网状支架在治疗复杂病变方面的局限性。然而，关于Lattice FD-MB治疗未破裂颅内动脉瘤（UIA）的疗效和安全性的临床数据仍然有限。本研究评估Lattice FD-MB在UIA治疗中的有效性和安全性。

方法

我们回顾性分析了2023年10月至2024年10月期间在本机构接受Lattice FD-MB治疗的29例UIA患者。术后进行数字减影血管造影（DSA）和计算机断层血管造影（CTA）以评估动脉瘤闭塞情况。在术后3、6和12个月进行临床随访，包括改良Rankin量表（mRS）评分和DSA。

结果

Lattice FD-MB在所有患者中均成功展开，手术成功率达100%，无术中与器械相关的失败情况。术中并发症发生2例（6.9%）。术后，27例患者（93.1%）显示出良好的临床结果，定义为无新的神经功能缺损或出血/缺血事件。出院时，功能结果（mRS）如下：23例患者（79.3%）为mRS 0（无症状），3例患者（10.3%）为mRS 1（无明显残疾），3例患者（10.3%）为mRS 2（轻度残疾）。随访时，mRS 0患者的比例随时间增加，3个月时为82.8%（24/29），6个月时为86.2%（25/29），12个月时为89.7%（26/29），表明临床持续稳定且神经功能有所改善。